Bio-Techne (TECH) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Bio-Techne (TECH) overview

Bio-Techne (TECH) stock analysis and AI equity research. For financial year 2026, Valuatum's model shows revenue of USD 1,215m and operating profit of USD 252m; the year-end share price was 70.65 USD and market capitalisation was USD 11,028m. Bio-Techne is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Bio-Techne's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 2,108mFY 2026
Share price70.65 USDFY 2026 year end
RevenueUSD 1,215mFY 2026
Operating profitUSD 252mFY 2026
Net earningsUSD 182mFY 2026
Market capitalisationUSD 11,028mFY 2026 year end

About Bio-Techne

Bio-Techne develops, manufactures, and sells life science reagents, instruments, and services for research, diagnostics, and bioprocessing markets. Its Protein Sciences products include biological reagents and analytical tools for protein analysis and assay workflows. Its Diagnostics and Spatial Biology offerings include diagnostic controls, calibrators, assays, tissue analysis instruments, and genetic and oncology kits for research and clinical applications.

Generate the Bio-Techne report

Bio-Techne is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Bio-Techne and represent financial year 2026. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Bio-Techne

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.